Mark H Tuszynski

Summary

Publications

  1. ncbi request reprint Growth-factor gene therapy for neurodegenerative disorders
    Mark H Tuszynski
    Department of Neurosciences, University of California at San Diego, and the Veterans Administration Medical Center San Diego, La Jolla 92093, USA
    Lancet Neurol 1:51-7. 2002
  2. ncbi request reprint Neurotrophic factors, gene therapy, and neural stem cells for spinal cord repair
    Armin Blesch
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Brain Res Bull 57:833-8. 2002
  3. ncbi request reprint Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord
    Laura Taylor
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA
    J Neurosci 26:9713-21. 2006
  4. ncbi request reprint A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
    Mark H Tuszynski
    Department of Neurosciences, University of California at San Diego, La Jolla 92093, USA
    Nat Med 11:551-5. 2005
  5. ncbi request reprint Growth factor gene therapy for Alzheimer disease
    Mark H Tuszynski
    Department of Neurosciences, Division of Neurosurgery, University of California at San Diego, La Jolla, California 92093, USA
    Neurosurg Focus 13:e5. 2002
  6. pmc IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury
    Edmund R Hollis
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Exp Neurol 215:53-9. 2009
  7. ncbi request reprint NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection
    Mark H Tuszynski
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Exp Neurol 181:47-56. 2003
  8. ncbi request reprint Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California, San Diego, La Jolla, CA 92093, USA
    Prog Brain Res 146:441-9. 2004
  9. ncbi request reprint Gene therapy for neurological disease
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Expert Opin Biol Ther 3:815-28. 2003
  10. ncbi request reprint New strategies in neural repair
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Prog Brain Res 138:401-9. 2002

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Growth-factor gene therapy for neurodegenerative disorders
    Mark H Tuszynski
    Department of Neurosciences, University of California at San Diego, and the Veterans Administration Medical Center San Diego, La Jolla 92093, USA
    Lancet Neurol 1:51-7. 2002
    ..The progress of gene-therapy clinical trials is aiding the transition to molecular and gene-targeted therapeutic approaches which have the potential to improve dramatically the prognosis of neurological disease...
  2. ncbi request reprint Neurotrophic factors, gene therapy, and neural stem cells for spinal cord repair
    Armin Blesch
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Brain Res Bull 57:833-8. 2002
    ..In this review we discuss the use of neural stem cell transplants and neurotrophic factor delivery by gene therapy to improve axonal regeneration in animal models of spinal cord injury...
  3. ncbi request reprint Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord
    Laura Taylor
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA
    J Neurosci 26:9713-21. 2006
    ..These findings indicate that a localized and continuous gradient of NT-3 can achieve axonal bridging beyond the glial scar, but growth for longer distances is not sustainable simply with a trophic stimulus...
  4. ncbi request reprint A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
    Mark H Tuszynski
    Department of Neurosciences, University of California at San Diego, La Jolla 92093, USA
    Nat Med 11:551-5. 2005
    ..05) increases in cortical 18-fluorodeoxyglucose after treatment. Brain autopsy from one subject suggested robust growth responses to NGF. Additional clinical trials of NGF for Alzheimer disease are warranted...
  5. ncbi request reprint Growth factor gene therapy for Alzheimer disease
    Mark H Tuszynski
    Department of Neurosciences, Division of Neurosurgery, University of California at San Diego, La Jolla, California 92093, USA
    Neurosurg Focus 13:e5. 2002
    ..In this article the authors summarize the development and implementation of nerve growth factor gene delivery as a potential means of reducing cell loss in AD...
  6. pmc IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury
    Edmund R Hollis
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Exp Neurol 215:53-9. 2009
    ..We conclude that developmental patterns of growth factor responsiveness are not simply recapitulated after adult injury, potentially due to post-natal shifts in patterns of IGF-I receptor expression...
  7. ncbi request reprint NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection
    Mark H Tuszynski
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Exp Neurol 181:47-56. 2003
    ..Thus, growth factor gene delivery can elicit growth of corticospinal axons in chronic stages of injury and improves functional outcomes compared to non-growth-factor-treated animals...
  8. ncbi request reprint Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California, San Diego, La Jolla, CA 92093, USA
    Prog Brain Res 146:441-9. 2004
    ....
  9. ncbi request reprint Gene therapy for neurological disease
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Expert Opin Biol Ther 3:815-28. 2003
    ..We have thereby begun the transition to molecular-based medicine which has the potential to alter the landscape and prognosis of neurological disease...
  10. ncbi request reprint New strategies in neural repair
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Prog Brain Res 138:401-9. 2002
  11. ncbi request reprint Clinical trials in spinal cord injury
    Andrew R Blight
    Acorda Therapeutics, Hawthorne, New York, USA
    J Neurotrauma 23:586-93. 2006
    ....
  12. ncbi request reprint Nerve growth factor gene therapy for Alzheimer's disease
    Mark H Tuszynski
    La Jolla, University of California San Diego, USA
    J Mol Neurosci 19:207. 2002
  13. ncbi request reprint Nerve growth factor gene delivery: animal models to clinical trials
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California San Diego, La Jolla, California 92093, USA
    Dev Neurobiol 67:1204-15. 2007
    ..This article reviews progress in evaluating the therapeutic potential of growth factors, from early animal models to human clinical trials currently underway in AD...
  14. ncbi request reprint Nerve growth factor gene therapy in Alzheimer disease
    Mark H Tuszynski
    Department of Neurosciences 0626, University of California San Diego, La Jolla 92161, and Veterans Affairs Medical Center, San Diego, CA, USA
    Alzheimer Dis Assoc Disord 21:179-89. 2007
    ..Gene therapy is one of a limited number of potential methods for achieving these requirements...
  15. ncbi request reprint Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury
    Armin Blesch
    Department of Neurosciences Center for Neural Repair, University of California, San Diego, La Jolla, CA 92093 0626, USA
    Yonsei Med J 45:28-31. 2004
    ..Thus, strategies have evolved for the delivery of potentially neuroprotective molecules, such as neurotrophic factors, and the replacement of cells and tissue lost due to CNS injury and degeneration...